. . . . . . . "[Fifty-five patients with clinical stage IIA-IIIC breast cancer received 12�weekly doses of paclitaxel (80�mg/m(2)) plus vorinostat (200-300�mg PO BID) on days 1-3 of each paclitaxel dose plus trastuzumab (for Her2/neu positive disease only), followed by doxorubicin/cyclophosphamide (60/600�mg/m(2) every 2�weeks plus pegfilgrastim).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:10:57+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .